Ocugen Provides Business Update with First Quarter 2026 Financial Results

About this update from Ocugen, Inc.

[{"type":"image","alt":"Ocugen","displaySize":"","headline":null,"caption":"Ocugen","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":171,"url":"https://media.zenfs.com/en/globenewswire.com/11651bb9383edc87dda9630a4828404a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Skm9e_O_sayLZV9VbrxBBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzOQ--/https://media.zenfs.com/en/globenewswire.com/11651bb9383edc87dda9630a4828404a","width":300,"height":171}},"lazy":false},{"type":"text","content":"Conference Call and Webcast Today at 8:30 a.m. ET","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p<0.05) 31% reduction in lesion size and 27% EZ preservation (correlated to visual function) in optimal dose for Phase 3","length":259,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"About 20% of patients demonstrated no progression of disease and 75% of subjects showed > 30% reduction in Iesion growth compared to control, with a favorable safety and tolerability profile","length":193,"tagName":"p"}]},{"val":[{"type":"text","content":"Allows robust registrational Phase 3 trial design, a potential combined U.S./EU trial with 300 subjects, with adaptive design powered at over 95%","length":145,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":338,"olType":false}]},{"val":[{"type":"text","content":"Trial enrollment complete for OCU400 for retinitis pigmentosa (RP) and OCU410ST for Stargardt disease registration trials, and on target to complete two Biologics License Application (BLA) submissions by 2027","length":208,"tagName":"p"}]},{"val":[{"type":"text","content":"The closing of a private offering of $115 million aggregate principal amount ($130 million if overallotment is exercised) of 6.75% convertible senior notes due 2034, with a conversion premium of 45%, is expected to extend cash runway into 2028, subject to customary closing conditions","length":284,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The Company expects to utilize $32.7 million of net proceeds from the Notes to retire the Avenue debt (12.5% interest rate) ","length":123,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":123,"ol...

More updates from Ocugen, Inc.